NAS:AGEN (USA) Also Trade In: Germany
Agenus Inc $ 3.90 0.46 (13.37%)
Warning! GuruFocus has detected 4 Severe warning signs with AGEN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Agenus Inc () from 2000 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Agenus stock (AGEN) PE ratio as of Jan 25 2021 is 0. More Details
Agenus PE Ratio (TTM) Historical Data
View and export this data going back to 2000. Start your Free Trial
Agenus PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:BSTC NAS:CTMX NAS:SYRS NAS:FULC NAS:XBIT NAS:MIRM NAS:RAPT NAS:PGEN NAS:MRUS NAS:CALA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 3 Forbes Road, Lexington, MA, USA, 02421-7305
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.